FDA Approves Lybrel
Rose A. Valenta — May 23, 2007 — Lifestyle
References: comcast.net
A USA-based Pharmaceutical company called Wyeth, plans to begin marketing Lybrel, its period suppression pill, in July 2007. The product comes in packs of 28 pills and contains low doses of ethinyl estradiol and levonorgestrel, two hormones that are commonly used in birth control pills. Side-effects in some women include unscheduled bleeding or spotting, which can last for a year while on the medication.
Implications - Lybrel was surprisingly approved by the Food and Drug Administration. The pill was made to terminate a woman's period for as long as she desired and therefore completely eliminate her chances of becoming pregnant. Since getting a period is a natural part of the body's process, you have to wonder if not ever getting it is actually safe?
Implications - Lybrel was surprisingly approved by the Food and Drug Administration. The pill was made to terminate a woman's period for as long as she desired and therefore completely eliminate her chances of becoming pregnant. Since getting a period is a natural part of the body's process, you have to wonder if not ever getting it is actually safe?
Trend Themes
1. Menstruation Suppression - Opportunity to develop innovative and safe methods of suppressing menstruation without affecting overall health.
2. Hormonal Birth Control - Potential for new forms of birth control that offer more control and options for women's reproductive health.
3. Alternative Medications - Rise in demand for alternative medications and treatments for menstrual pain and discomfort.
Industry Implications
1. Pharmaceutical - Pharmaceutical companies can explore the development of new and improved menstruation suppression medications.
2. Women's Health - Opportunity for companies to focus on innovative solutions for women's reproductive health and contraception.
3. Alternative Medicine - Growth in demand for natural and holistic approaches to menstrual health and well-being.
2.3
Score
Popularity
Activity
Freshness
